Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

Aurobindo Pharma sets up new subsidiary Avogent Lifesciences

Aurobindo Pharma has incorporated a new wholly-owned subsidiary, Avogent Lifesciences Private Limited, to handle manufacturing and marketing in India and abroad. The company also announced that its subsidiary Lannett Company LLC has launched a generic version of Advair Diskis in the US.

By Tertius News AI Desk 2 distinct · 2 mastheads · 2 articles Version 1 Coverage Sep 1, 2026 Published 1h ago

Aurobindo Pharma has incorporated a new subsidiary, Avogent Lifesciences Private Limited, to undertake manufacturing and marketing operations in India and foreign countries. The entity was incorporated on August 31, 2026, with an initial share capital of ₹5 crore.

According to a regulatory filing, Avogent Lifesciences is a wholly owned subsidiary of Apitoria Pharma Private Limited, which is itself a wholly owned subsidiary of Aurobindo Pharma. The new entity operates in the pharmaceuticals sector and has been formed to align with Aurobindo's core business focus. The transaction involves a 100% cash subscription to Avogent's share capital by Apitoria, with the initial subscription being 50 lakh equity shares of ₹10 each.

The company stated that Avogent is a related party because it is owned through Apitoria, but Aurobindo's promoters and promoter group have no interest in the transaction. No governmental or regulatory approvals were required for the incorporation, and no completion timeline applies because the subsidiary has already been incorporated. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In a separate development, Aurobindo Pharma's subsidiary Lannett Company LLC has launched a generic version of Advair Diskus in the US on August 31, 2026. The product is available in 100/50 mcg and 250/50 mcg strengths, marking the first commercial inhalation product from the company's pipeline. Advair Diskus is a widely used combination inhaler prescribed for the management of asthma and chronic obstructive pulmonary disease (COPD). The launch represents a significant step for Lannett as it brings its first inhalation product to the US market, potentially expanding patient access to this therapy.

How each outlet told it

A framing line is our reading of that outlet's own text — an interpretation, not a quotation and not a fact we assert. Check it against what the outlet published.

scanx.trade

Framing: Announces the incorporation of a new subsidiary for manufacturing and marketing

as of Sep 1, 2026, 6:15 AM UTC

Facts Included:

Aurobindo Pharma has incorporated a new subsidiary, Avogent Lifesciences Private Limited, to undertake manufacturing and marketing operations in India and foreign countries.
The entity was incorporated on August 31, 2026, with an initial share capital of ₹5 crore.
It is structured as a wholly owned subsidiary of Apitoria Pharma Private Limited, which is itself a wholly owned subsidiary of Aurobindo Pharma.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Share structure: 50,00,000 equity shares of ₹10 each
The promoters and promoter group of Aurobindo Pharma have no interest in the transaction.
No governmental or regulatory approvals were required for the incorporation.
Aurobindo Pharma's subsidiary Lannett Company LLC has launched a generic version of Advair Diskus in the US on August 31, 2026.
The product is available in 100/50 mcg and 250/50 mcg strengths, marking the first commercial inhalation product from the company's pipeline.
Advair Diskus is a widely used combination inhaler prescribed for the management of asthma and chronic obstructive pulmonary disease (COPD).

Read the source article →

The Times of India

Framing: The headline emphasizes the corporate action: Aurobindo Pharma's arm Apitoria incorporates a new subsidiary named Avogent Lifesciences.

as of Sep 1, 2026, 5:19 PM UTC

Facts Included:

Aurobindo Pharma on Tuesday said its wholly-owned subsidiary, Apitoria Pharma Private Limited, has incorporated Avogent Lifesciences Private Limited as a new wholly-owned subsidiary in India.
Avogent, incorporated on Aug 31, 2026, will operate in the pharmaceuticals sector and has been formed to undertake manufacturing and marketing operations in India and overseas, aligning with Aurobindo’s core business focus.
The transaction involves a 100% cash subscription to Avogent’s share capital by Apitoria.
The initial subscription is Rs 5 crore, comprising 50 lakh equity shares of Rs 10 each.
Avogent is a related party because it is owned through Apitoria, but the company’s promoters and promoter group have no interest in the transaction.
No governmental or regulatory approvals are required for the incorporation, and no completion timeline applies because Avogent has already been incorporated.

Read the source article →

What was claimed, and who backed it

AI-extracted; can misattribute a claim — see Methodology.

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status is Contested when two claims on this page negate each other; otherwise it counts the distinct outlets we found asserting that specific claim — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimAurobindo Pharma has incorporated a new subsidiary, Avogent Lifesciences Private Limited, to undertake manufacturing and marketing operations in India and foreign countries.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via scanx.trade as of Sep 1, 2026, 6:15 AM UTC, The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimAvogent Lifesciences Private Limited was incorporated on August 31, 2026.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via scanx.trade as of Sep 1, 2026, 6:15 AM UTC, The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimAvogent Lifesciences Private Limited has an initial share capital of ₹5 crore.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via scanx.trade as of Sep 1, 2026, 6:15 AM UTC, The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimAvogent Lifesciences Private Limited is a wholly owned subsidiary of Apitoria Pharma Private Limited, which is itself a wholly owned subsidiary of Aurobindo Pharma.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via scanx.trade as of Sep 1, 2026, 6:15 AM UTC, The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimThe disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.	ConfidenceHigh	StatusSingle-source via scanx.trade as of Sep 1, 2026, 6:15 AM UTC
ClaimAvogent Lifesciences Private Limited's share structure is 50,00,000 equity shares of ₹10 each.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via scanx.trade as of Sep 1, 2026, 6:15 AM UTC, The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimThe promoters and promoter group of Aurobindo Pharma have no interest in the transaction involving the incorporation of Avogent Lifesciences.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via scanx.trade as of Sep 1, 2026, 6:15 AM UTC, The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimNo governmental or regulatory approvals were required for the incorporation of Avogent Lifesciences.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via scanx.trade as of Sep 1, 2026, 6:15 AM UTC, The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimAurobindo Pharma's subsidiary Lannett Company LLC has launched a generic version of Advair Diskus in the US on August 31, 2026.	ConfidenceHigh	StatusSingle-source via scanx.trade as of Sep 1, 2026, 6:15 AM UTC
ClaimThe generic version of Advair Diskus is available in 100/50 mcg and 250/50 mcg strengths.	ConfidenceHigh	StatusSingle-source via scanx.trade as of Sep 1, 2026, 6:15 AM UTC
ClaimThe generic version of Advair Diskus is the first commercial inhalation product from Aurobindo Pharma's pipeline.	ConfidenceHigh	StatusSingle-source via scanx.trade as of Sep 1, 2026, 6:15 AM UTC
ClaimAdvair Diskus is a widely used combination inhaler prescribed for the management of asthma and chronic obstructive pulmonary disease (COPD).	ConfidenceHigh	StatusSingle-source via scanx.trade as of Sep 1, 2026, 6:15 AM UTC
ClaimAurobindo Pharma said the transaction involves a 100% cash subscription to Avogent's share capital by Apitoria.	ConfidenceHigh	StatusSingle-source via The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimAurobindo Pharma said Avogent is a related party because it is owned through Apitoria.	ConfidenceHigh	StatusSingle-source via The Times of India as of Sep 1, 2026, 5:19 PM UTC
ClaimAurobindo Pharma said no completion timeline applies because Avogent has already been incorporated.	ConfidenceHigh	StatusSingle-source via The Times of India as of Sep 1, 2026, 5:19 PM UTC

Transparency & Audit Trail

2 distinct · 2 mastheads · 2 articles consulted: scanx.trade, The Times of India 15 claims extracted Version 1 Written 2026-09-01